Argenx stock lost a third of its value as the Amsterdam biotech said a late-stage trial did not meet primary or secondary endpoints. The Phase 3 study was of.
European stocks finished lower Tuesday, with the Stoxx Europe 600 index falling 0.30% to 457.04. The French CAC 40 index fell 0.21% to 7,250.13, the FTSE 100.